BioSpace News Archive

Agiomix has received the ISO 15189:2012 Accreditation from the Emirates International Accreditation Centre for Next Generation Sequencing clinical assays.

Over 80 percent overall survival rates at two years among patients with complete response (CR) as well as among patients with partial response (PR)

US-based biotech company VLP Therapeutics, Inc. announced on March 15 that it has raised US$16 million in a Series A funding round from MIYAKO Capital Co., Ltd., Sojitz Corporation, Konishiyasu Co., Ltd., in Japan and three existing investors in the US for research and development of a cancer treatment vaccine.

Core One Labs Inc. is pleased to announce that the Financial Industry Regulatory Authority has accepted the Company’s Form 211 for filing and that its common shares will commence trading in the United States on the OTC Pink Market under the ticker symbol “CLABF”.

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, announced that the company has been selected as an eligible stock in the Shenzhen-Hong Kong Stock Connect, effective from March 15, 2021.

PharmaEssentia Corporation, a global biopharmaceutical innovator leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced that the U.S. Food and Drug Administration has issued a complete response letter for the company’s Biologics License Application for ropeginterferon alfa-2b-njft for the treatment of polycythemia vera, a rare blood cancer.

Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing, and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, announced the appointment of Ms. Minyoung Kim as General Manager of Antengene South Korea.